skip to main content

Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardBreast CancerBreast CancerSCE Medical Oncology

A patient has germline BRCA2-mutated, ER-positive/HER2-negative metastatic breast cancer. She previously received an anthracycline and taxane and has progressed after endocrine therapy. Which finding most directly establishes eligibility for the PARP-inhibitor option in NICE TA1040?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — The complete BRCA1/2, HER2-negative and prior-therapy criterion set

TA1040 is defined by BRCA1/2 mutation, HER2-negative advanced breast cancer and the required prior anthracycline/taxane and endocrine exposure or unsuitability. PIK3CA, PALB2, HER2-low status and TMB do not substitute for those appraisal criteria.

Reference: NICE TA1040: olaparib for BRCA-positive HER2-negative advanced breast cancer. https://www.nice.org.uk/guidance/ta1040/chapter/1-Recommendations